10061038EndoPore: Tumour targeted non-viral delivery for RNA therapeuticsClosedCollaborative R&DInnovate UKA new wave of RNA-therapeutics has the potential to transform outcomes for patients with cancers which do not respond to existing small molecule or antibody treatments. RNA-therapeutics have come to the forefront on the back of Covid vaccine success, and many Biotechs are now developing these for currently non-responding patient groups. This £6Bn potential market of new RNA-therapeutics needs a safe drug-delivery technology: to protect the therapeutics from degradation within the body, to target them to the tumour, and to release them inside the cells. Vitarka is a UK life sciences technology SME which is developing a novel intracellular delivery technology, Endo-Pore. Endo-Pore is a drug delivery technology which will carry RNA-therapeutics through the body and then release them within tumour cells - opening up many currently validated but undruggable targets for new anti-cancer treatments. Through this grant, we will substantially de-risk the development path by establishing robust _in vivo_ efficacy of our technology in delivering a clinically relevant therapeutic drug molecule into tumours. We will start validating clinically relevant formulations and define the roadmap for regulatory interaction. This will position the programme for larger scale private investment, and for partnership with biotechs for clinical trials, thereby enabling rapid technological and commercial impact for Vitarka and UK.